66 FR 72 pgs. 19176-19177 - Agency Information Collection Activities; Submission for OMB Review; Comment Request; Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Addition of “Geriatric Use” Subsection in the Labeling
Type: NOTICEVolume: 66Number: 72Pages: 19176 - 19177
Docket number: [Docket No. 00N-1674]
FR document: [FR Doc. 01-9119 Filed 4-12-01; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 00N-1674]
Agency Information Collection Activities; Submission for OMB Review; Comment Request; Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Addition of "Geriatric Use" Subsection in the Labeling
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995 (PRA).
DATES:
Submit written comments on the collection of information by May 14, 2001.
ADDRESSES:
Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: Wendy Taylor, Desk Officer for FDA.
FOR FURTHER INFORMATION CONTACT:
Karen L. Nelson, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION:
In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Addition of "Geriatric Use" Subsection in the Labeling (OMB Control No. 0910-0370)-Extension
Section 201.57(f)(10) (21 CFR 201.57(f)(10)) requires that the "Precautions" section of prescription drug labeling must include a subsection on the use of the drug in elderly or geriatric patients (aged 65 and over). The information collection burden imposed by this regulation is necessary to facilitate the safe and effective use of prescription drugs in older populations. The geriatric use subsection enables physicians to more effectively access geriatric information in physician prescription drug labeling.
| 21 CFR Section | No. of -Respondents per Response | Annual Frequency per -Response | Total Annual -Responses | Hours per -Response | Total Hours |
|---|---|---|---|---|---|
| 201.57(f)(10)-new drug -applications | 83 | 1.49 | 124 | 8 | 992 |
| 201.57(f)(10)-abbreviated new drug applications | 117 | 3.96 | 464 | 2 | 928 |
| Total | 1,920 | ||||
| 1 There are no capital costs or operating and maintenance costs associated with this collection of information. | |||||
In the Federal Register of January 5, 2001 (66 FR 1142), the agency requested comments on the proposed collections of information. No significant comments were received.
Dated: April 6, 2001.
William K. Hubbard,
Senior Associate Commissioner for Policy, Planning, and Legislation.
[FR Doc. 01-9119 Filed 4-12-01; 8:45 am]
BILLING CODE 4160-01-S